Drug Trial Radar · NCT07794748
A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
4,701
Actual
Start
Sep 8, 2026
Primary completion
Apr 26, 2027
Study completion Apr 26, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide safety data and demonstrate lot consistency with the PG4 vaccine by evaluating the immunogenicity of 3 different lots of this vaccine. This study will compare a new pneumococcal vaccine with the vaccine currently in use to see if they are similarly safe. It will also compare three batches of the new vaccine to make sure they work the same way. Blood samples will be taken to measure how the body responds to the vaccines. The study will be conducted in the United States. Participants will be assigned to 1 of 4 groups. Group 1: PG4 vaccine lot 1; Group 2: PG4 vaccine lot 2; Group 3: PG4 vaccine lot 3; Group 4: 20vPnC. Within each group, participants will be assigned by chance in a 2:2:2:1 ratio to receive 1 vaccine injection (shot) with either PG4 (new vaccine) lot 1, PG4 lot 2, PG4 Lot 3 or 20vPnC, given in the arm. This means that for every 7 participants, about 2 will receive either PG4 lot 1, lot 2 or lot 3 and about 1 will receive 20vPnC. Each participant will take part in the study for approximately 6 months.
Conditions
- Pneumococcal Disease
Interventions
PG4 Multivalent VaccineBiological
Multivalent Pneumococcal Vaccine
PG4 Multivalent VaccineBiological
Multivalent Pneumococcal Vaccine
PG4 Multivalent VaccineBiological
Multivalent Pneumococcal Vaccine
20 Valent Pneumococcal Conjugate Vaccine (20vPnC)Biological
20 Valent Pneumococcal Conjugate Vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Prespecified Local Reactions Within 7 Days After VaccinationTime frame: Within 7 days after Vaccination
- Percentage of Participants reporting Prespecified Systemic Events Within 7 Days after VaccinationTime frame: Within 7 days after Vaccination
- Percentage of Participants with Adverse Events (AEs)Time frame: From Vaccination to 1 month after Vaccination
- Percentage of Participants with Serious Adverse Events (SAEs)Time frame: From Vaccination to 6 months after Vaccination
- OPA geometric mean ratios (GMR) between each pair of PG4 vaccine lotsTime frame: 1 month after Vaccination
Locations
37 sites in 1 country. Site status is shown where the registry gives one.
Achieve Clinical Research, LLC d/b/a Accel Research Sites - Birmingham Clinical Research Unit
Birmingham, Alabama
Orange County Research Center
Lake Forest, California
Diablo Clinical Research, LLC dba Flourish Research
Walnut Creek, California
Clinical Research Consulting
Milford, Connecticut
Suncoast Research Associates
Doral, Florida
Research Centers of America
Hollywood, Florida
East Coast Institute for Research, LLC
Jacksonville, Florida
Entrust Clinical Research
Miami, Florida
Palm Springs Community Health Center
Miami Lakes, Florida
Indago Research and Health Center, Inc.
Miami Lakes, Florida
Innovation Medical Research, LLC
Palmetto Bay, Florida
Palm Beach Research Center
West Palm Beach, Florida
Javara Inc.
Fayetteville, Georgia
Clinical Research Atlanta
Stockbridge, Georgia
East-West Medical Research Institute
Honolulu, Hawaii
DM Clinical Research
Melrose Park, Illinois
Velocity Clinical Research, Sioux City
Sioux City, Iowa
Henry Ford St. John Hospital - Thomas Mackey Center for Infectious Disease Research
Grosse Pointe Woods, Michigan
Clinical Research Professionals
Chesterfield, Missouri
Bio-Kinetic Clinical Applications, LLC dba QPS-MO
Springfield, Missouri
Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment Center
Springfield, Missouri
Sundance Clinical Research, LLC
St Louis, Missouri
Velocity Clinical Research, Grand Island
Grand Island, Nebraska
South Jersey Infectious Disease
Somers Point, New Jersey
Accellacare - Wilmington
Wilmington, North Carolina
Cincinnati Children's Hospital Medical Center Investigational Drug Services
Cincinnati, Ohio
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio
CTI Clinical Research Center
Cincinnati, Ohio
DM Clinical Research
Philadelphia, Pennsylvania
Clinical Trials of South Carolina
Moncks Corner, South Carolina
TMA Headlands LLC (d/b/a Trial Management Associates)
Myrtle Beach, South Carolina
Coastal Carolina Research Center, LLC
North Charleston, South Carolina
SMS Clinical Research LLC
Mesquite, Texas
DM Clinical Research - Sugar Land
Sugar Land, Texas
DM Clinical Research
Tomball, Texas
J. Lewis Research, Inc. / Foothill Family Clinic
Salt Lake City, Utah
J. Lewis Research, Inc. / Foothill Family Clinic South
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.